Study of rare enzyme disorders in monoclonal gammopathy or myeloma
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks for two rare inherited disorders—Gaucher disease and acid sphingomyelinase deficiency (ASMD)—in people who already have a blood condition like monoclonal gammopathy (abnormal protein) or multiple myeloma. If you have an enlarged spleen or low platelets, you may be eligible to help researchers understand if these rare diseases are more common in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You have an enlarged spleen (felt at least 1 cm below your ribs) or your spleen was removed for a reason not related to liver problems.
- Or you have low platelet counts (thrombocytopenia) that were there before you started treatment for your blood disorder.
- You are willing and able to give consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study screens people with an enlarged spleen and low platelet count for two rare genetic conditions: Gaucher disease and acid sphingomyelinase deficiency (ASMD). It aims to find people who might have these treatable disorders.
This study tests people who have interstitial lung disease (a type of lung scarring) and certain other signs, like an enlarged spleen or low blood platelets, to see if they have a rare genetic condition called acid sphingomyelinase deficiency/Niemann-Pick disease types A and B.
This study follows the natural history of ASMD, a rare enzyme deficiency. It can help researchers understand how the condition progresses in both adults and children.
This study follows people with rare genetic conditions (GM1, GM2, sialidosis, or galactosialidosis) that affect how the body breaks down certain substances in cells. Researchers track how these diseases progress to better understand them and potentially help future patients.
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
Hear when a new Gaucher Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.